Annals of Surgical Oncology Sign the Guestbook
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Originally published as Ann Surg Oncol Early Release 10.1245/ASO.2004.03.019 on January 12, 2004

Annals of Surgical Oncology 11:173-177 (2004)
© 2004 Society of Surgical Oncology
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rossi, C. R.
Right arrow Articles by Lise, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rossi, C. R.
Right arrow Articles by Lise, M.
Related Collections
Right arrow Chemotherapy
Right arrow Surgery

ORIGINAL ARTICLES

Hyperthermic Isolated Limb Perfusion With Low-Dose Tumor Necrosis Factor-{alpha} and Melphalan for Bulky In-Transit Melanoma Metastases

Carlo Riccardo Rossi, MD, Mirto Foletto, MD, Simone Mocellin, MD, Pierluigi Pilati, MD and Mario Lise, MD

From the Clinica Chirurgica Generale II, Dipartimento di Scienze Oncologiche e Chirurgiche, Università di Padova, Padova, Italy.

Correspondence: Address correspondence and reprint requests to: Carlo Riccardo Rossi, MD, Clinica Chirurgica Generale II, Dipartimento di Scienze Oncologiche e Chirurgiche, Università di Padova, Via Giustiniani, 2, 35128 Padova, Italy; Fax: 39-049-651891; E-mail: carlor.rossi{at}unipd.it

Background: Melphalan (L-PAM) hyperthermic isolated limb perfusion (HILP) is currently considered the standard treatment for patients with in-transit metastases from cutaneous melanoma. We here report on the results of L-PAM and low-dose tumor necrosis factor (TNF){alpha} HILP in patients with bulky disease.

Methods: Twenty patients underwent TNF{alpha} (1 mg) and L-PAM (10 mg/L) HILP. Perfusion was performed for 90 minutes, and systemic leakage was strictly monitored. Locoregional toxicity was evaluated according to Wieberdink’s criteria, whereas tumor response was evaluated with physical examination and ultrasound scan with or without fine-needle aspiration of any suspected recurrence.

Results: In all cases, systemic leakage was <5%. No postoperative deaths occurred, and locoregional toxicity was mild (grade 1 or 2) in 95% of patients. A complete tumor response was obtained in 14 patients (70%), and partial responses were obtained in 5 patients (25%). After a median follow-up of 18 months, six patients are alive and disease free, seven are alive with local or distant recurrence or both, and seven have died of disease.

Conclusions: Low-dose TNF{alpha} HILP can achieve tumor responses comparable with those reported with higher doses of cytokine. Moreover, this drug regimen is associated with acceptable local toxicity, carries a smaller risk of systemic toxicity, and incurs lower costs.

Key Words: Melanoma • Isolated limb perfusion • TNF{alpha} • Melphalan




This article has been cited by other articles:


Home page
 Ann. Surg. Oncol.Home page
C. R. Rossi, F. Russano, S. Mocellin, V. Chiarion-Sileni, M. Foletto, P. Pilati, L. G. Campana, A. Zanon, G. F. Picchi, M. Lise, et al.
TNF-Based Isolated Limb Perfusion Followed by Consolidation Biotherapy with Systemic Low-dose Interferon Alpha 2b in Patients with In-transit Melanoma Metastases: A Pilot Trial
Ann. Surg. Oncol., April 1, 2008; 15(4): 1218 - 1223.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
F. J. Lejeune and A. M.M. Eggermont
Hyperthermic Isolated Limb Perfusion With Tumor Necrosis Factor Is a Useful Therapy for Advanced Melanoma of the Limbs
J. Clin. Oncol., April 10, 2007; 25(11): 1449 - 1450.
[Full Text] [PDF]

Home page
 Ann. Surg. Oncol.Home page
A. J. Hayes, S. J. Neuhaus, M. A. Clark, and J. M. Thomas
Isolated Limb Perfusion With Melphalan and Tumor Necrosis Factor {alpha} for Advanced Melanoma and Soft-Tissue Sarcoma
Ann. Surg. Oncol., January 1, 2007; 14(1): 230 - 238.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
W. R. Cornett, L. M. McCall, R. P. Petersen, M. I. Ross, H. A. Briele, R. D. Noyes, J. J. Sussman, W. G. Kraybill, J. M. Kane III, H. R. Alexander, et al.
Randomized Multicenter Trial of Hyperthermic Isolated Limb Perfusion With Melphalan Alone Compared With Melphalan Plus Tumor Necrosis Factor: American College of Surgeons Oncology Group Trial Z0020
J. Clin. Oncol., September 1, 2006; 24(25): 4196 - 4201.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
R. van Horssen, T. L. M. ten Hagen, and A. M. M. Eggermont
TNF-{alpha} in Cancer Treatment: Molecular Insights, Antitumor Effects, and Clinical Utility.
Oncologist, April 1, 2006; 11(4): 397 - 408.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
S. Bonvalot, A. Laplanche, F. Lejeune, E. Stoeckle, C. Le Pechoux, D. Vanel, P. Terrier, J. Lumbroso, M. Ricard, G. Antoni, et al.
Limb salvage with isolated perfusion for soft tissue sarcoma: could less TNF-{alpha} be better?
Ann. Onc., July 1, 2005; 16(7): 1061 - 1068.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
S. Mocellin, M. Provenzano, C. R. Rossi, P. Pilati, R. Scalerta, M. Lise, and D. Nitti
Induction of Endothelial Nitric Oxide Synthase Expression by Melanoma Sensitizes Endothelial Cells to Tumor Necrosis Factor-Driven Cytotoxicity
Clin. Cancer Res., October 15, 2004; 10(20): 6879 - 6886.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Surg. Oncol.Home page
J. H. W. de Wilt and a. J. F. Thompson
Is there a Role for Isolated Limb Perfusion With Tumor Necrosis Factor in Patients With Melanoma?
Ann. Surg. Oncol., February 1, 2004; 11(2): 119 - 121.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2004 by the Society of Surgical Oncology.